Lamictal

Lamictal is an antiepileptic drug belonging to the lamotrigine group.

Producing countries: Great Britain (Glaxo, Glaxo Wellcome, GlaxoSmithKline Pharmaceuticals S.A. companies), Poland.

Manufacturers: Wellcome Ltd (UK), Glaxo (UK), Glaxo Wellcome (UK), GlaxoSmithKline Pharmaceuticals S.A. (Poland).

International name: Lamotrigine.

Synonyms: Vero-Lamotrigine, Lamitor, Lamolep.

Dosage forms: tablets 25 mg, 50 mg, 100 mg, 5 mg; Chewable/soluble tablets 5 mg, 25 mg, 100 mg.

Ingredients: active substance - lamotrigine.

Indications for use: epileptic seizures (tonic-clonic, partial, generalized), Lennox-Gastaut syndrome (resistant forms).

Contraindications: hypersensitivity, severe liver dysfunction, liver failure, pregnancy, lactation, age under 12 years.

Side effects: headache, dizziness, drowsiness, sleep disturbances, fatigue, aggressiveness, confusion, nausea, liver dysfunction, leukopenia, thrombocytopenia, allergic reactions.

Drug interactions: accelerates elimination when used together with other anticonvulsants and paracetamol.

Overdose: ataxia, nystagmus, drowsiness, headache, vomiting, coma. Treatment: gastric lavage, activated carbon.

Special instructions: gradual withdrawal to avoid increased frequency of seizures.

Literature: Encyclopedia of Medicines (2002, 2006).